No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a.

Mark S Freedman,Giancarlo Comi,Patricia K Coyle,Julie Aldridge,Liang Chen,Kurt Marhardt,Ludwig Kappos

Multiple Sclerosis and Related Disorders（2020）

引用 3|浏览38

暂无评分

摘要

•This analysis compared subcutaneous IFN β-1a with placebo on achieving (NEDA)−3.•Early vs delayed subcutaneous IFN β-1a resulted in higher odds of achieving NEDA-3.•Treatment differences were sustained in the long-term (up to 5 years).•Those with Gd+ lesions had a lower chance of remaining NEDA-3 than those without.•This study supports treatment ASAP after a first clinical demyelinating event.

查看译文

关键词

Interferon β1a,Multiple sclerosis,No evidence of disease activity,Clinically isolated syndrome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要